Mechanisms of resistance to vascular endothelial growth factor blockade (Q37956587)

25 August 2017

Mechanisms of resistance to vascular endothelial growth factor blockade (English)

1 reference

25 August 2017

0 references

Shaad E Abdullah

1

1 reference

PubMed ID

22086782

25 August 2017

Roman Perez-Soler

series ordinal

2

1 reference

PubMed ID

22086782

25 August 2017

language of work or name

English

0 references

publication date

15 November 2011

1 reference

25 August 2017

1 reference

25 August 2017

118

1 reference

25 August 2017

3455-3467

1 reference

25 August 2017

14

1 reference

Aristotle: the first student of angiogenesis.

25 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

Mechanisms of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

Intussusceptive angiogenesis--the alternative to capillary sprouting

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

Mechanisms of angiogenesis and arteriogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

Hemostatic regulators of tumor angiogenesis: a source of antiangiogenic agents for cancer treatment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

Tumorigenesis and the angiogenic switch

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

Clinical applications of angiogenic growth factors and their inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

Tumor angiogenesis: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

The preclinical evaluation of angiogenesis inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

Thrombospondin-2: a potent endogenous inhibitor of tumor growth and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

Fighting cancer by attacking its blood supply

21 January 2018

2 references

https://api.crossref.org/works/10.1002%2FCNCR.26540

21 January 2018

https://api.crossref.org/works/10.1002%2FCNCR.26540

7 January 2021

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

What makes vessels grow with exercise training?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

The role of myeloid cells in the promotion of tumour angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

Vascular endothelial growth factor is a secreted angiogenic mitogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

Angiopoietin-1 promotes endothelial cell proliferation and migration through AP-1-dependent autocrine production of interleukin-8.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

Insulin-like growth factor I is required for vessel remodeling in the adult brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

Regulation of angiogenesis by hypoxia: role of the HIF system

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

Syndecans: multifunctional cell-surface co-receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

Integrins in angiogenesis and lymphangiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

Angiogenesis: an organizing principle for drug discovery?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

Snake venom Vascular Endothelial Growth Factors (VEGF-Fs) exclusively vary their structures and functions among species

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

VEGFs and receptors involved in angiogenesis versus lymphangiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

VEGFs, receptors and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

The semaphorins: versatile regulators of tumour progression and tumour angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

Angiogenesis in pre-malignant conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

How Avastin potentiates chemotherapeutic drugs: action and reaction in antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

Targeting the VEGF pathway: antiangiogenic strategies in the treatment of non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

Phase 1 study of the investigational, oral angiogenesis inhibitor motesanib in Japanese patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

Clinical translation of angiogenesis inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

Comprehensive dissection of PDGF-PDGFR signaling pathways in PDGFR genetically defined cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

Fibroblast growth factors/fibroblast growth factor receptors as targets for the development of anti-angiogenesis strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

Modes of resistance to anti-angiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

VEGF-A and FGF-2 synergistically promote neoangiogenesis through enhancement of endogenous PDGF-B-PDGFRbeta signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

Drug resistance associated with antiangiogenesis therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

Lymphangiogenesis in development and human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

Effect of p53 status on tumor response to antiangiogenic therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

Origin and function of tumor stroma fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

Pericytes and vessel maturation during tumor angiogenesis and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

Contribution of granulocyte colony-stimulating factor to the acute mobilization of endothelial precursor cells by vascular disrupting agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

All angiogenesis is not the same: Distinct patterns of response to antiangiogenic therapy in experimental neuroblastoma and Wilms tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

Bevacizumab for patients with metastatic renal cancer: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

21 January 2018

Cancer without disease.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

Tumor-associated endothelial cells with cytogenetic abnormalities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

Vascular remodeling and clinical resistance to antiangiogenic cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

Tumour vascularization: sprouting angiogenesis and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

Antiangiogenic agents and HIF-1 inhibitors meet at the crossroads.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or - dacarbazine in patients with stage IV metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

Combined targeting of interleukin-6 and vascular endothelial growth factor potently inhibits glioma growth and invasiveness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

Delta-like 4/Notch signaling and its therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

Anti-angiogenesis: new concept for therapy of solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

7 January 2021

The role of vascular endothelial growth factor genetic variability in cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

7 January 2021

Antiangiogenic therapy: a universal chemosensitization strategy for cancer?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

7 January 2021

Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

7 January 2021

Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

7 January 2021

A new perspective on tumor endothelial cells: unexpected chromosome and centrosome abnormalities

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

7 January 2021

Patterns of angiogenesis in nonsmall-cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26540

7 January 2021

Identifiers

DOI

10.1002/CNCR.26540

1 reference

25 August 2017

1 reference

PubMed ID

22086782